1. Home
  2. RLTY vs MDWD Comparison

RLTY vs MDWD Comparison

Compare RLTY & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest

RLTY

Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest

HOLD

Current Price

$14.51

Market Cap

245.8M

Sector

Finance

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$16.78

Market Cap

224.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RLTY
MDWD
Founded
2022
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Investment Managers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
245.8M
224.6M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
RLTY
MDWD
Price
$14.51
$16.78
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
51.7K
67.6K
Earning Date
01-01-0001
03-05-2026
Dividend Yield
9.35%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$57.63
Revenue Next Year
N/A
$26.44
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.90
$14.14
52 Week High
$15.97
$22.51

Technical Indicators

Market Signals
Indicator
RLTY
MDWD
Relative Strength Index (RSI) 27.80 43.75
Support Level $14.45 $16.68
Resistance Level $15.30 $18.58
Average True Range (ATR) 0.25 0.59
MACD -0.12 -0.02
Stochastic Oscillator 4.87 27.29

Price Performance

Historical Comparison
RLTY
MDWD

About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest

Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: